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Abstract 
Background: Mesenchymal stromal cells (MSC) are largely investigated in clinical trials aiming to control inappro-
priate immune reactions (GVHD, Crohn’s disease, solid organ transplantation). As the percentage of MSC precursors 
in bone marrow is very low, these must be expanded in vitro to obtain therapeutic cell doses. We describe here the 
constitution of an allogeneic human third-party MSC bank from screened healthy volunteer donors in compliance 
with quality specifications and ISCT-release criteria and report follow-up of different aspects of this activity since 2007.
Methods: 68 clinical-grade large-scale MSC cultures were completed and analyzed. The whole process was 
described, including volunteer donor screening, bone marrow collection, mononuclear cell isolation and expansion 
over 4 weeks, harvesting, cryopreservation, release, administration and quality controls of the cells (including microbi-
ology, phenotype, and potency assays).
Results: From 59 validated donors, 68 cultures were completed (mean of final yields: 886 × 106 cells/culture) and 
a total of 464 MSC aliquots have been produced and stored in liquid nitrogen (mean of 132.8 × 106 cells/bag). Each 
MSC batch underwent extensive testing to verify its conformity with EBMT and ISCT release criteria and was individu-
ally validated. As of June 1 2015, 314 bags have been released and infused to patients included in 6 different clinical 
protocols. All thawed MSC units satisfied to release criteria and no infusion-related toxicity was reported.
Conclusion: In conclusion, despite low passage cultures, we have been able to create an allogeneic “off-the-shelf” 
MSC bank with a large number of frozen aliquots and report here an efficient clinical-grade MSC banking activity in 
place for more than 7 years. Our challenge now is to produce MSC in compliance with good manufacturing practices 
(GMP) as, in the meantime, MSC have become considered as advanced therapy medicinal products (ATMP). Another 
significant challenge remains the development of relevant potency assay.
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Background
Mesenchymal stromal cells (MSC) were identified more 
than three decades ago by Friedenstein et al. as the stro-
mal cells of the marrow microenvironment that support 
hematopoiesis [1]. MSC are multipotent progenitors 
capable of differentiating into various cells and tissues, 
such as chondrocytes, osteoblasts and adipocytes [2, 3].
In addition to multilineage differentiation and partici-
pation in the hematopoietic niche, MSC exert powerful 
immunomodulatory effects that include: inhibition of 
proliferation and function of T and B cells, inhibition of 
dendritic cell maturation and function and immune mod-
ulation of other immune cells such as natural killer (NK) 
cells and macrophages [4–6]. Due to the absence of co-
stimulatory molecules and low HLA class I expression, 
MSC are not thought to be prone to immune rejection 
[7, 8]. This makes them ideal candidates for allogeneic 
use in both regenerative medicine and clinical applica-
tions in immune diseases such as graft-versus-host dis-
ease (GVHD), Crohn’s disease (CD), rheumatoid arthritis 
(RA) among others [9].
The International Society for Cellular Therapy (ISCT) 
has established the minimum criteria to define MSC 
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spindle-shaped, plastic-adherent cells isolated from bone 
marrow, adipose tissue, and many other tissue sources 
such as umbilical cord or cord blood. They must express 
certain cell surface markers (CD73, CD90, CD105) and 
lack expression of others (CD45, CD34, CD14, HLA-DR) 
and have the capacity to differentiate into osteoblasts, 
adipocytes and chondroblasts when cultured in particu-
lar in vitro conditions [10, 11]. Prior to clinical applica-
tion, MSC must be significantly expanded to obtain 
therapeutic cell doses. Traditionally, MSC are obtained 
by ex  vivo culture of the adherent cell fraction of bone 
marrow aspirates. The percentage of MSC among mar-
row cells is very low (0.01 to 0.001 % depending on age) 
but they can be easily isolated and expanded to reach 
adequate numbers for therapeutic doses. For this reason, 
cell processing facilities have established procedures for 
large scale production of MSC.
In the Laboratory of Cell and Gene Therapy (LTCG, 
CHU of Liège), we started in late 2006 a “MSC bank” 
based on clinical-grade expansion of MSC from BM sam-
ples obtained from healthy volunteer donors. Cells are 
produced according to the European Group for Blood 
and Marrow Transplantation (EBMT) consortium rec-
ommendations for defining common procedures for 
MSC isolation and expansion, as well as common release 
criteria, enabling multicenter trials with comparable 
MSC products [12]. Our first pilot clinical protocol (20 
patients) evaluated the safety and preliminary efficacy 
of MSC to prevent graft rejection and GVHD after allo-
geneic hematopoietic cell transplantation (HCT) with 
non-myeloablative conditioning (NMHCT) [13]. In this 
study, HLA-mismatched NMHCT with MSC co-infusion 
appeared to be safe. Also, the prevention of death from 
GVHD and preservation of GVT effects suggested by this 
study are currently under investigation in a multicenter 
randomized study of MSC co-transplantation in patients 
given HLA-mismatched PBSC after non-myeloablative 
conditioning (NCT01045382).
We are currently involved in six clinical trials of MSC 
infusion in different settings including HSC transplan-
tation (HCT) with myeloablative or non-myeloablative 
conditioning, cord blood transplantation (CBT), solid 
organ transplantation and severe or refractory autoim-
mune disorders such as Crohn’s disease. According to 
each protocol, the MSC dose varies from 1 to 4  ×  106 
MSC/kg per infusion.
In this paper, we demonstrate the feasibility and 
describe the difficulties of setting up a large MSC bank 
from allogeneic donors for use in academic clinical tri-
als. The whole process is described, including volunteer 
donor screening, bone marrow collection, mononuclear 
cell isolation and expansion over 4  weeks, harvesting, 
cryopreservation, release, administration and quality 
controls of the cells. The results of the 68 clinical-grade 
MSC cultures completed in 7  years of activity are also 
summarized. Finally, future challenges in MSC banking 
are also discussed and particularly the translation of the 




The study was approved by the human and animal Ethics 
Committees of the University of Liege. Written informed 
consent was obtained from all bone marrow donors in 
accordance with the Declaration of Helsinki.
Allogeneic volunteer MSC donors were recruited 
among medical school students and hospital personnel 
and bone marrow samples collected exclusively at the 
CHU of Liège. The donor had to fill in a questionnaire 
to identify potential risks of disease transmission and 
the answers were analyzed according to a standardized 
interpretation checklist. The donor was then examined 
by a Senior Hematologist and a series of blood tests were 
obtained in hematology, general chemistry and serology 
(HBS Ag, HBC Ab, HIV Ab, HCV Ab, Syphilis + Nucleic 
Acid Testing for HIV-HBV-HIV). MSC donor eligibility 
criteria are similar to those of HSC donors but applied in 
a more restrictive fashion. For example, urgent medical 
need (UMN) was never considered for donor eligibility 
and virtually all donor non-conformities are considered 
as absolute contraindications. In some clinical trials, 
additional donor eligibility criteria may be applied. If 
found eligible, the donor had to sign an informed consent 
form and the marrow collection was scheduled within 
30  days of the screening visit using standardized pre-
scription form.
Bone marrow collection
Briefly, bone marrow (50 ± 10 ml) was collected from the 
posterior iliac crest under local anesthesia in sterile con-
ditions into sterile heparin-containing syringes. The phy-
sician completed a standardized bone marrow collection 
report. Then, syringes were immediately transported at 
room temperature to the LTCG where they were received 
by trained cell processing laboratory staff. At the time of 
reception, each syringe was inspected and its appearance, 
identifiers and time of reception was documented before 
being processed within 30 min. We always worked with 
fresh, never with frozen, bone marrow.
Initiation of in vitro MSC cultures (Fig. 1)
MSC expansion cultures and quality controls were car-
ried out as described in relevant SOP of the Laboratory 
of Cell and Gene Therapy (LTCG) at the CHU of Liege. 
Bone marrow was first transferred under laminar air flow 
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in sterile tubes and a sample taken for analysis before 
dilution 1:1 with PBS buffer (Miltenyi Biotec). Isolation 
of mononuclear cells (MNC) from diluted bone marrow 
was obtained by FicollR density gradient (GE Healthcare, 
Amersham Biosciences, Upsala, Sweden) and centrifuga-
tion at 450 g during 20 min. Since 2013, the manual pro-
cedure has been changed for an automatized and closed 
Ficoll procedure using the SepaxR device (Biosafe, Eysins, 
Switzerland). Implementation of the SepaxR system was 
performed after formal validation of the method accord-
ing to the results of three separate experiments initiated 
to compare manual versus automated Ficoll mononuclear 
cell isolation. MSC produced from MNC obtained by 
both methods satisfied to their specifications. The Sepax 
system was implemented because it was safer (closed sys-
tem) and MNC contained more CFU-F, leading to more 
performant cultures.
After washing (PBS), 28  ×  106 cells were seeded per 
175  cm2 sterile tissue culture flasks (FalconR) in Dul-
becco’s Modified Eagles Medium–Low Glucose with 
Glutamax (DMEM-GLX, Fisher-Bioblock, Invitro-
gen, Merelbeke, Belgium) supplemented with 10  % 
gamma-irradiated Fetal Bovine Serum (FBS, Hyclone, 
Perbio Sciences, Utah USA) and antibiotics (Penicillin/
Streptomycin (P/S), Lonza, Petit-Rechain, Belgium) in 
a final volume of 28  mL. The flasks were incubated in 
an incubator at 37  °C, 5 % CO2 and 90 ± 5 % humidity. 
Adherent precursors were selected by removing non-
adherent cells after 3 days and MSC were then expanded 
by replacement of the media twice a week. Cultures were 
monitored by microscopic observation for morphology 
and bacterial or yeast contamination. After generally 
2 weeks of culture, MSC colonies were confluent (±70 %) 
and had to be replated.
MSC trypsinisation and replating (1st and 2nd passages, 
Fig. 1)
When MSC were nearly confluent (70  %), they were 
trypsinized and replated at a lower density (4000  cells/
cm2) to allow further cell expansion (first passage). 
Briefly, cells were first washed twice with phosphate-
buffered saline (PBS), before incubation with trypsin–
EDTA (Fisher-Bioblock, Invitrogen, Merelbeke, Belgium) 
for 5 min at 37 °C. Then, they were collected and washed 
Post-Ficoll
MNC
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Fig. 1 MSC clinical expansion. From ±50 mL of initial fresh BM, MNC cells were isolated by manual or automated ficoll isolation and seeded in T175 
flasks. After a P0 expansion of 14 days, cells were harvested and re-loaded in new flasks for P1 expansion. One week later, cells were harvested and 
re-loaded according to the same scheme for P2 expansion before a final harvest around day 28. Quality controls were performed at different stages 
of the process
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before cell counting (trypan blue dye exclusion) on 
a Neubauer cell counting chamber. After dilution at 
the appropriate density in the complete culture media 
(DMEM + FBS + P/S, see above), cells were replated in T 
flasks and incubated at 37 °C with medium refreshed after 
3 days. One week later, cells had generally reached ±70 % 
confluence and were replated for the second time accord-
ing to the same procedure (second passage). At that time, 
several quality controls were performed (see below).
MSC harvest (Fig. 1)
After a total of 4 weeks of culture (around day 28), MSC 
were generally ready for harvesting. Indeed, 1 week after 
the second passage, the cells have normally reached again 
more than 70 % confluence. They were first washed twice 
with phosphate-buffered saline (PBS) before incuba-
tion with trypsin–EDTA a few minutes at 37  °C. Cells 
were then collected in a harvest medium (PBS/5 % FBS), 
washed and then resuspended in an administration buffer 
[PBS/2.5  % human serum albumin (HSA)]. MSC were 
then washed in administration buffer before cell count on 
a Neubauer cell counting chamber and diluted at 2 × 106 
cells/ml (in administration buffer) before freezing. At 
that time, several quality controls were performed (see 
below).
MSC cryopreservation
The MSC suspension (2  ×  106 cells/ml administra-
tion buffer) was transferred in appropriate sterile freez-
ing bags (cryoMACSR, Miltenyi Biotec GmbH, Bergisch 
Gladbach, Germany). Aliquots containing 10  ×  106 to 
190  ×  106 cells were prepared depending on the num-
ber of harvested cells. Then, the freezing solution (40 % 
PBS + 40 % of a 20 % HSA solution + 20 % DMSO) was 
added v/v to the cell suspension under agitation at 4  °C 
and cryopreservation was carried out with an automated 
cryofreezer (Thermoforma, Thermo Electron, Ohio) 
according to the following program:
Duration 60 min until −160 °C
Steps of the programme
 Step 1 4 °C during 10 min
 Step 2 ⇩ à 1.5 °C/min until −12 °C
 Step 3 ⇩ à 45 °C/min until −50 °C
 Step 4 ⇧ à 9 °C/min until −28 °C
 Step 5 −20 °C during 5 min
 Step 6 ⇩ à 1 °C/min until −35 °C
 Step 7 ⇩ à 1.5 °C/min until −45 °C
 Step 8 ⇩ à 6 °C/min until −160 °C
 Step 9 −160 °C during 99 min
Each bag was considered as a MSC unit and stored in 
the vapor phase of a liquid nitrogen tank until validation 
and release for clinical use.
Placebo preparation
As placebos were required in the context of some ran-
domized clinical trials, placebo batches were prepared 
(and frozen) according to the same procedure as the 
cell suspension (but without addition of cells). Briefly, 
the placebo preparation consisted in the administration 
buffer (PBS/2.5  % HSA) that is transferred in appropri-
ate sterile bags (see above). The freezing solution (40  % 
PBS + 40 % HSA + 20 % DMSO) was added v/v to the 
placebo solution under agitation at 4 °C and cryopreser-
vation was carried out with an automated cryofreezer 
(Thermoforma, Thermo Electron, Ohio). Placebo bags 
are then stored in the vapor phase of liquid nitrogen until 
clinical use. When a placebo is requested for injection, 
it is thawed, diluted with PBS and injected according 
to exactly the same procedure as for cell products (see 
below). The only quality controls performed on placebo 
consist in sterility testing before cryopreservation as well 
as upon thawing. Endotoxin and mycoplasma were not 
tested on placebo preparations.
Quality controls and traceability (Table 1)
Donor recruitment, bone marrow collection, MSC 
expansion culture, freezing and quality controls were 
carried out as described in relevant SOPs of the LTCG. 
From the bone marrow collection, during all steps of cul-
ture and cryopreservation, samples and cell containers 
(T-flasks, freezing bags) are labeled according to ISBT 
standards ensuring sustained traceability of the cellular 
product.
All components (equipment, starting cellular material, 
reagents, materials, personnel and methods) used in the 
manufacturing process were recorded.
At each step of the MSC expansion process, cells were 
submitted to quality controls (see below). Some of these 
were only informative while others were considered 
as release criteria according to the EBMT guidelines 
(Table 1).
We did not verify the absence of adventitious agents 
in FBS or Trypsin–EDTA. For this assessment, we 
relied on reagent certificates of analysis provided by the 
manufacturers.
Phenotypic characterization of MCS
Analysis of cell-surface molecules was performed on MSC 
cultures using flow cytometry. Harvested cells were washed 
with PBS containing 5 % HSA. Around 2 × 105 cells were 
resuspended in 90 μL PBS containing 5 % HSA, and incu-
bated for 10 min on ice in the dark, with the following MAb: 
APC-conjugated CD73 (IgG1, AD2 clone), PE-conjugated 
CD105 (IgG1, 43A4E1 clone), FITC-conjugated CD90 
(IgG1, DG3 clone), PerCP-conjugated HLADR (IgG2a, 
AC122 clone), vioblue-conjugated anti-CD45 (IgG2a, 
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5B1 clone), vioblue-conjugated anti-CD14 (IgG2a, TÜK4 
clone), vioblue-conjugated anti-CD34 (IgG2a, AC136 
clone), vioblue-conjugated anti-CD3 (IgG2a, BW264/56 
clone). Cells incubated with their corresponding isotype 
control (IgG1 PE, FITC and APC: IS5-21F5 clone, IgG2a 
vioblue and PerCP: S43.10 clone Miltenyi Biotec) were also 
included. Data were acquired on a Macsquant Flow Cytom-
eter (Miltenyi Biotec) by collecting a minimum of 10,000 
events and analyzed with Macsquantify software.
Mesenchymal stromal cells differentiation assays
Fat, bone and cartilage differentiation assays were car-
ried out as described by Pittenger et al. [2] and revealed 
by staining with oil red O, alizarin red and toluidine blue, 
respectively. Differentiation media were home-made.
MSC immunosuppression assays
1 × 104 MSC were plated in triplicates in round-bottom 
96-well plates (Becton–Dickinson) in a total volume of 
100  μl of RPMI 1640 medium supplemented with 10  % 
FBS, 100  U/ml penicillin, 100  mg/ml streptomycin, 
l-glutamine (2  mM) (all from Lonza), sodium pyruvate 
(100 mM), non-essential amino acid (NEAA) (100 mM) 
and 5  ×  10−5 M β-mercaptoethanol (β-ME) (all from 
Gibco, Merelbeek, Belgium). After 4-hour incubation, 
MSC were irradiated at 25  Gy using a 137Cs source 
(GammaCell 40, Nordion, Ontario, Canada).
Allogeneic human peripheral mononuclear cells 
(PBMC) were isolated from a blood sample (healthy vol-
unteer donor) by Ficoll PaqueR Plus density gradient. 
PBMC (5  ×  104 or 1  ×  105) were then added to wells 
in a total volume of 200  μl containing or not irradiated 
MSC, in the presence of anti-αCD3/CD28 microbeads 
(Invitrogen, Dynal A/S, Oslo, Norway). Co-cultures with-
out anti-αCD3/CD28 microbeads were used as controls. 
Cells were then incubated at 37 °C in 5 % humidified air 
for 4 days. Cell cycle analysis of PBMC stimulated or not 
with anti-αCD3/CD28 microbeads and cultivated dur-
ing 4  days with or without MSC were performed using 
CycleTESTR Plus DNA Reagent Kit (Becton–Dickin-
son). The percentage of cells in the different phases of the 
cell cycle was determined with the Macsquant Software 
(Miltenyi) or the Modfit Software (Becton–Dickinson). 
The effect of MSC on PBMC stimulation responses was 
calculated as percentage suppression compared with the 
proliferative response in the positive control without 
MSC (+- standard deviation of the mean). The positive 
control was set to 0 % suppression.
Cytogenetics
Karyotyping was performed at the Genetics Department 
of the Hospital by the Q-banding technique and analyzed 
with CytovisionR software.
Microbiology testing
MSC sterility was assessed by bacterial culture (aero-
bia, anaerobia and fungi with BactalertR; Microbiology 
department of the Hospital), mycoplasma screening 
(luminometry, MycoalertR, Lonza; Microbiology depart-
ment of the Hospital) and endotoxin detection (limulus 
test, European pharmacopeia 2.6.14, Pharmacy depart-
ment of the Hospital).
MSC release and thawing (Table 1b)
MSC are only prescribed and infused in the context of a 
clinical trial. Thus, patient eligibility/inclusion criteria, 
clinical evaluation and laboratory testing are protocol-
specific and listed in each of the respective clinical trial 
descriptions. If the patient is eligible according to all pro-
tocol criteria, he must sign the study informed consent 
form to allow release of the cells (a frozen MSC product is 
released for clinical use specifically for a patient according 
to the prescribed MSC dose and the patient weight).
If MSC are delivered to a patient inside the hospi-
tal, they are thawed at the LTCG. Briefly, the MSC bag 
is protected in a sterile plastic bag and thawed in a 37 °C 
water bath for a few minutes. If the MSC bag is in a dual 
packaging (bags cryopreserved after April 2008), the bag 
is just immersed in the water bath a few seconds to take 
off easily the second packaging. Then the bag in its first 
packaging is quickly thawed in the water bath in a ster-
ile protective bag. The bag is taken out of the water when 
the access sites are just thawed; there must still be small 
ice clots in the bag. Then, the bag is quickly transferred 
under the laminar flow and immediately perforated with 
a sampling-site coupler and diluted with a PBS buffer 
[1:0.75 (MSC solution:PBS)] (Clinical Grade, Miltenyi 
Biotec, Utrecht, The Netherlands) to avoid DMSO toxic-
ity. Quality controls are performed after thawing of the 
cells (Table 1b). Numeration and viability are assessed by 
trypan blue coloration and cell count on a Neubauer cell 
counting chamber. We thus chose this method because it 
was easy and rapid (MSC must be infused as quickly as 
possible after thawing) and we did not have a flow cytom-
eter available in the clean room to rapidly use other cell 
counting methods (7-AAD, PI). Besides, we do not rou-
tinely re-assess phenotype, mycoplasma and endotoxins 
after thawing. Indeed freezing/thawing steps have been 
validated with all critical QC parameters meeting eligibil-
ity criteria (Table 2c). In addition, as thawed cells must be 
infused as soon as possible, it is not possible to proceed 
with these QC before infusion. Moreover, the only new 
reagent introduced during the thawing step is PBS which 
is devoid of mycoplasma and endotoxins.
The cell product is then transferred in an appropri-
ately labeled sterile transfer bag and transported to the 
hematology department of the hospital for infusion to 
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the patient. The released MSC product can also be trans-
ferred frozen in a dry-shipper at −160  °C to another 
center for infusion after inclusion of a patient in a mul-
ticenter clinical protocol. Upon preparation before ship-
ment, the bag canister, dry shipper and protective box 
are labeled as described in the transportation SOP. The 
shipper is placed in a protective box and transported by 
a specialized transporter ordered by the destination hos-
pital. In the recipient tissue bank, cells are then thawed 
according to the LTCG standard procedure.
Population doubling level (PDL) calculation
PDL was calculated according to the formula PDL = 3.322 
(log Y−log I) where Y =  number of cells harvested and 
I = number of cells inoculated at P1.
Doubling time (DT) estimation
Doubling time (DT) was calculated according to the for-
mula DT =  t ×  log (2)/log (number of cells harvested/
number of cells inoculated), where t is the time in hours 
between passage 1 and harvest of the cells.
Table 2 MSC culture process validation
Results of three large-scale MSC cultures for initial process validation: culture rates, phenotypes at final harvest and post-thaw parameters are reported
(a) Cultures rates
1st Exp. 2nd Exp. 3rd Exp.
BM sample (mL) 28 52 55
MNC on day 0 180 × 106 195 × 106 260 × 106
MSC on day 28 225 × 106 165 × 106 356 × 106
(b) Phenotypes
Marker Eligibility criteria (%) 1st Exp. (%) 2nd Exp. (%) 3rd Exp. (%) Conformity
CD73 >70 96.9 99.9 99.4 Ok
CD105 >70 85.6 90.3 77.8 Ok
CD90 >70 100 98.2 100 Ok
CD34 <10 1.8 8.8 0.92 Ok
CD45 <10 1.1 1.10 0.55 Ok
HLA-DR <10 0.84 0.63 0.52 Ok
CD80 <10 1.0 0.7 0.45 Ok
CD31 <10 1.0 0.9 0.62 Ok
(c) Post-thaw
Test Eligibility criteria 1st Exp. 2ndExp. 3rd Exp. Conformity
Initial cell number Na 100 × 106 70 × 106 55 × 106 Na
Initial viability Na 95.8 % 82.5 % 86.0 % Na
Post-thaw cell count Na 100 × 106 56 × 106 43 × 106 Na
Post-thaw cell viability >50 % 89.5 % 78.0 % 78.0 % Ok
Post-thaw cell culture expansion Na Ok Ok Ok Na
Sterility Sterile Ok Ok Ok Ok 
Mycoplasma Absence of mycoplasma Ok Ok Ok Na 
Endotoxin Endotoxin level <2.5 U.I./ml Ok Ok Ok Na 
Phenotype
CD73 >70 % 99.5 % 96.1 % 87.9 % Ok
CD105 >70 % 93.6 % 70.3 % 70.0 % Ok
CD90 >70 % 100 % 99.6 % 99.8 % Ok
CD34 <10 % 3.1 % 2.7 % 2.6 % Ok
CD45 <10 % 1.0 % 1.9 % 1.0 % Ok
HLA-DR <10 % 1.0 % 1.2 % 1.0 % Ok
CD80 <10 % 0.4 % 0.8 % 0.4 % Ok
CD31 <10 % 0.6 % 1.2 % 0.6 % Ok
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Statistics
Results are reported as mean  ±  standard error of the 
mean (SEM). Comparisons between conditions were 
made using Student unpaired  t  tests with GraphPad 




After a few small-scale MSC expansions to set up the 
process, three large-scale clinical MSC cultures were ini-
tiated for validation with three different bone marrow 
(BM) samples obtained from healthy volunteer donors. 
All quality controls fulfilled pre-defined qualification cri-
teria (Table 2).
Freezing/thawing steps were also validated. For each 
previous culture, frozen MSC were thawed and criti-
cal parameters were evaluated. Again, all quality con-
trols met eligibility criteria (Table 2c). Thawed cells were 
also devoid of bacterial, mycoplasma and endotoxin 
contamination.
Shelf life determination of the product after thawing 
was also assessed. Cells from four different bags were left 
(or not = control) in the post-thaw buffer at room tem-
perature for different times (1, 2, 4H). At each time point, 
cell count and viability were assessed. Viability and cell 
count seemed stable for 2 h but drop significantly when 
kept for longer periods. Cells were also seeded in culture 
flasks to test their proliferation potential. When replated, 
the cell proliferative potential was affected as early as 
after 1 h in the post-thaw buffer.
The effects of long-term cryopreservation were not sys-
tematically addressed. However, three MSC bags were 
thawed after 7–8  years of storage and showed excellent 
post-thaw viability (80, 77 and 83  %, respectively) and 
recovery (83, 71 and 94 %, respectively). This indicates a 
good stability of the cell product during long-term stor-
age in liquid nitrogen. Systematic evaluation of long-term 
MSC stability is scheduled for future batches produced 
under GMP recommendations.
MSC banking
After appropriate validation, we started in November 
2006 a clinical-grade third party MSC bank following the 
EBMT manufacturing process.
During the past 7.5  years, 61 donors were screened. 
One donor was discarded for multiple allergies and col-
lection was technically impossible for another one. From 
the 59 validated donors (36 females and 23 males), 70 
large-scale MSC expansions were initiated and completed 
(Table  3). Donors were between 18 and 52  years of age 
(median 26.7 years). There is no standard for MSC donor 
age. Ten percent (7/68) of our donors were older than 
40 years and 90 % were between 18 and 40, with a mean 
of 29 years. The older donors were collected at the begin-
ning of our banking activity, but now we select donors 
younger than 40 years of age. Volumes of collected bone 
marrow ranged from 25 to 70  mL (median 50  mL) and 
total number of mononucleated cells obtained after ficoll 
ranged from 124 to 956 × 106 (median 280 × 106).
All the initiated cultures except two gave rise to colo-
nies and completed the MSC culture process resulting in 
1 to 45 MSC unit bags per culture. A total of 464 MSC 
bags have been produced and stored from the 68 com-
pleted cultures (Table 3; Fig. 2).
Table 3 MSC production between 2007 and 2015
Criteria Min. Max. Median
MSC culture parameters
 Donor age (years) 18 52  26.7
 BM sample volume (mL) 25 70  50
 Mononuclear cells post-Ficoll (×106) 124 956  280
 CFU-F (number per 2 × 106 cells) 2 96  25
 Final MSC yields (×106) 19 5431  546
 PDL (P1-harvest) 2.38 7.18 4.69
 DT in hours (P1-harvest) 46.8 141 71.7
 Viability (%) 72 100  85
 Number of aliquots (=bags)/culture 1 45  4
 Number of cells/aliquot (×106) 19 189  110
Fig. 2 MSC banking: production and release activity. a Production: 
From 59 validated donors, 68 cultures were completed allowing 
freezing of 464 MSC bags. From these, 430 are already validated, 18 
non-compliant and 16 are still awaiting validation. b Release: Since 
2007, 314 bags have been released. From those, 290 were MSC and 
24 placebo; 187 were released on site and 103 were sent to other 
Belgian centers
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Final yields ranged from 19 × 106 to 5431 × 106 cells 
with a median of 546  ×  106 cells per culture. Popula-
tion doubling levels (PDL) between passage 1 and pas-
sage 3 (harvest) ranged from 2.38 to 7.18 with a median 
of 4.69. Doubling times (DT) ranged from 46.8 to 141 h 
with a median of 71.7 h. We didn’t observe any correla-
tion between age and Colony-Forming Units or between 
CFU-F and yield of the culture/mL BM processed (data 
not shown). However, although sex didn’t influence the 
yield of CFU-F (P = 0.55), male BM samples gave rise to 
significantly higher total cell yields compared to cultures 
obtained from female BM samples (P = 0.0011).
Viability at harvesting was generally excellent with a 
mean of 88.9 ± 5.5 %. All the harvested MSC were fro-
zen in adequate aliquots at −160  °C in liquid nitrogen. 
Aliquots contained various numbers of cells in order to 
cover a wide range of patient weights, considering that 
the ideal MSC dose is ranging between 1–4  ×  106/kg 
recipients. MSC were stored in bags containing between 
19 × 106 and 189 × 106 cells with a mean of 132.8 × 106 
cells per bag. We did not freeze standardized quantities 
because the required cell count for infusion is defined by 
the protocol in which the patient is included as a weight-
based dose. The acceptable dose is always within a speci-
fied range, for example 1–2 or 3–4 × 10E6 cells/kg. The 
minimal cell count is the minimal acceptable dose of 
viable cells multiplied by the patient’s weight. So when 
a patient is included in a clinical trial, we choose an ali-
quot containing the optimal amount of cells according to 
the dose prescribed in the study and the patient weight. 
In this context, cell doses as small as 20 × 10E6 cells can 
be stored and released for low-weight patients (pediatric 
cases).
All cultures were initiated with fresh cells but due to 
technical limitations, a maximum of 300 T175 cm2 were 
replated at passage 2. If cell number exceeded this capac-
ity, the cells were frozen at P2 and thawed later to allow 
further expansion and final harvest. Each harvest gave 
rise to one MSC batch so that one culture can generate 
one or more batches.
The large range in the final yields is due to variability 
in the intrinsic quality of the collected BM and also to 
variability in the efficiency of the different FBS batches 
(always pre-validated but some were better than others). 
As explained in the text, two cultures did not expand and 
were discarded. No T flask was discarded. Noteworthy, 
the extreme expansion rates (low and high) were rare, 
with most cultures (>80 %) yielding >200 × 106 cells.
Quality controls and compliance with release criteria
Each MSC batch underwent extensive testing to verify 
its conformity with release criteria and was individually 
validated. EBMT release criteria were applied to release 
batches but retrospective analysis revealed that cells were 
also compliant with the stricter ISCT phenotype criteria 
(>95 % expression CD90, CD105, CD73; <2 % for CD14, 
CD45, CD34 and <1 % for CD3). HLA-DR expression was 
also evaluated for all produced batches and was always 
below 2 % at harvest, but this was not a release criterion.
All but 3 batches satisfied to release criteria. Indeed, 
the batches from two cultures had to be discarded for 
non-conformity due to a donor constitutional anomaly 
detected by karyotypic analysis and further confirmed by 
analysis of donor lymphocytes. One batch was discarded 
due to a positive bacteriology result. MSC were also 
evaluated in a stimulation assay by incubation with anti-
CD3/CD28. As shown in Fig.  3, proliferation of stimu-
lated PBMC was significantly reduced by the addition 
of MSC [mean inhibition (10/1 ratio): 41  ±  9  %, range 
25–57  %]. Thawed cells were cultured and also demon-
strated good inhibitory properties (>25 % inhibition in a 
10/1 ratio; data not shown). In summary, 464 MSC bags 
have been produced and frozen in our facility during 
the past 7  years (Fig.  2). Among them, 430 (93  %) have 
already been validated according to EBMT consortium 
release criteria and 16 are still awaiting validation. Eight-
een bags had to be discarded (3.9 %) (Fig. 2).
All placebo bags were sterile and fulfilled release 
criteria.
MSC release and thawing
All MSC products validated for clinical use were listed 
according to their cellular content, which enabled us 
to choose the adapted MSC product for each patient 
according to his/her weight and the dose specifications of 
the clinical trial in which the patient was included.
When a patient is included in a clinical trial, the 
selected MSC bag(s) is (are) released and thawed for infu-
sion. Thawed MSC are quickly diluted with buffer and an 
aliquot is collected to assess MSC numeration and viabil-
ity. If cell recovery is adequate for dose specifications and 
viability above 50  %, MSC infusion is allowed. Thawed 
cells must be infused as soon as possible and in all cases 
within 1 h after thawing. In order to respect the set time 
limit, before each scheduled infusion, we verify that the 
patient is in good condition and ready to receive the MSC 
before thawing the bag.
As of June 1 2015, 314 bags have been released (24 pla-
cebo and 290 MSC bags) and infused to patients. Among 
these, 103 were transported frozen to other Belgian cent-
ers before being thawed on site and 187 were prepared in 
the LTCG (Fig. 2b).
Mean viability at freezing was 90 ± 4 % (Fig. 4a), rang-
ing from 80 to 100 %. Viability dropped to 76 ± 9 % after 
thawing (range 50 % to 96 %). The mean decrease of via-
bility during thawing was 14 % (P < 0.0001). However, all 
Page 10 of 15Lechanteur et al. J Transl Med  (2016) 14:145 
thawed MSC units satisfied to release criteria as none 
showed viability below 50 %. To our knowledge, there is 
no standard in Europe for viability of such products and 
this 50 % viability cutoff was accepted by our regulatory 
authorities. However, the mean viability of our MSC 
after thawing was 76 ± 9 % (Fig. 4a) which is quite higher 
indeed. Noteworthy, very few bags showed viabilities 
between 50 and 60 % (3/167 = 1.8 %).
The mean cell content of the released bags was 
136.6 ± 28.8 × 106 cells (range 65 to 189 × 106) before 
freezing (Fig.  4b) and 111  ±  30.5  ×  106 after thaw-
ing (range 45.5 to 189 ×  106), with a mean recovery of 
81 ± 13 % (range 50 to 115 %) (Fig. 4c).
All thawed bags (MSC and Placebo) were subjected to 
bacteriological analysis and results were all negative.
Post‑thaw MSC potency
In order to evaluate post thaw MSC immunosuppressive 
properties, five MSC bags were thawed in separate exper-
iments. Cells were washed in tubes and resuspended 
in complete media before being plated in T175  cm2 
flasks. At different time points (day 1, 2, 3 and 4), cells 
were detached and evaluated for different parameters: 
recovery (compared to the number of seeded cells after 
Fig. 3 MSC immunosuppressive properties. Inhibition of PBMC prolif-
eration by third party MSC: PBMC (100,000 or 50,000) were stimulated 
(S-PBMC) with anti-αCD3/CD28 microbeads during 4 days with or 
without irradiated (25 Gy) MSC (10/1 or 5/1 PBMC/MSC ratios) added 
at the beginning of the culture. Proliferation was assessed by analysis 
of the cell cycle by flow cytometry (N = 28). Result are expressed as 
the percentage of cells present in S + G2 M phases (a) and as the 
percentage of inhibition compared to the stimulated PBMC condition 



































































Fig. 4 MSC post-thaw viability and cell recovery. Pre- and post-thaw 
MSC viability (a), MSC number (b), as well as recovery of cell number 
(c) (N = 170)
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washing), viability, phenotype, differentiation and immu-
nosuppressive properties. Thawed MSC demonstrated 
very poor PBMC inhibition capacities in MLR assays (day 
1: 3 ± 4 %; day 2: 10 ± 7 %; (Table 4). Indeed, 3 days of 
culture were necessary to restore a full and stable PBMC 
inhibition ability (day 3: 40 ± 9 %; day 4: 42 ± 2 %; day 5: 
43 ± 1 %) (Table 4; Fig. 5). 
Recoveries were very low until day 4 (Fig.  5) before a 
slight increase thereafter indicating that cells had begun 
to re-proliferate. Thus, restoration of MSC immunosup-
pressive properties correlated with a stop in MSC loss. 
Nevertheless, cells did not require re-culture to maintain 
their differentiation capacities towards adipocytic, osteo-
blastic and chondroblastic lineages.
Discussion
The purpose of this paper was to demonstrate the feasibil-
ity and describe the difficulties of setting up a large MSC 
bank from allogeneic donors for use in academic clinical 
trials. The constitution of a human third-party MSC bank 
from screened healthy volunteer donors and the follow-
up of different aspects of this activity since 2007 are devel-
oped. Results from 68 large scale clinical expansions are 
described and discussed. Methods of generating clinical-
grade MSCs have already been described by other groups 
but, to our knowledge, this is the first paper describing 
such a large and detailed banking experience [14, 15].
The absence of co-stimulatory molecules and human 
leucocyte antigen (HLA) class II molecules, as well as 
low HLA class I expression on MSCs, make them ideal 
for allogeneic use. MSC produced and used in our clini-
cal trials are of allogeneic origin but do not seem to elicit 
immune responses. Indeed, HLA-mismatched MSC 
manufactured by the same process were shown to be 
weakly immunogenic after infusion into HSCT recipi-
ents [16]. One concern when expanding large number 
of MSC is the number of passages required to meet dose 
requirements. Some studies indicate that MSC proper-
ties change with passages and that immunosuppressive 
capacities become less potent when multiplying passages 
[17, 18]. Von Bar et al. published recently clinical results 
that suggest that acute GVHD patients treated with early 
passage MSC had a better survival than those treated 
with late passage cells [19]. In our manufacturing pro-
cess, MSC are only cultured for three passages (14 days 
of primary culture and 2 passages of 7 days each). This is 
quite low and comparable to a MSC culture process yield-
ing comparable cell numbers in four shorter passages 
as reported by Sabatino et  al. [14]. However, it is now 
generally accepted that MSC will begin to senesce after 
a certain number of cell divisions and that this is best 
Table 4 MSC thawing: pre and  post-thaw MSC immuno-
suppressive properties
Results are shown for MSC recovery, viability and immunosuppressive properties 
(%) at different times after thawing and replating in T-flasks with complete 
media
(%) Min. Max. Mean ± SD
Day 0 Recovery 61 84 72.8 ± 10.4
Viability 61 71 65.1 ± 4.4
Immunosuppression 5 5 5.0 ± 0.0
Day 1 Recovery 21 54 41.8 ± 12.9
Viability 86 91 88.8 ± 2.1
Immunosuppression 0 10 2.9 ± 4.1
Day 2 Recovery 19 40 30.3 ± 11.3
Viability 78 87 83.9 ± 4.0
Immunosuppression 4 19 10.3 ± 7.4
Day 3 Recovery 21 36 26.8 ± 10.8
Viability 74 97 85.5 ± 16.3
Immunosuppression 34 47 40.5 ± 8.6
Day 4 Recovery 21 34 28.3 ± 6.5
Viability 89 93 90.3 ± 2.3
Immunosuppression 40 43 41.8 ± 2.2
Day 5 Recovery 31 42 36.3 ± 7.5
Viability 85 91 88.0 ± 4.2
Immunosuppression 42 44 42.6 ± 1.3
Fig. 5 MSC post-thaw immunosuppressive properties. MSC bags 
were thawed (N = 5), washed and replated in flasks in complete 
media. Immunosuppressive properties (a) and cell recoveries (b) were 
evaluated at different time points after thawing
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evaluated by their population doubling level (PDL) rather 
than by the number of passages or the duration of cul-
ture. As it is very difficult to evaluate the starting number 
of MSC in the initial culture (mixture of mononuclear 
cells), most labs start counting MSC cumulative popu-
lation doubling at the end of the primary culture (first 
passage). The calculated PDL of our MSC culture ranged 
from 2.38 to 7.18 with a median of 4.69. This is consist-
ent with standard MSC protocols showing 2.5–3 popu-
lation doublings per passage. Moreover, the observed 
PDL are still below the PDL correlating with occurrence 
of MSC senescence (PDL from 10 to 40). However, the 
PDL of these cells in  vivo before collection of the BM, 
which also depends on donor age, are not known. Dur-
ing our large culture experience, we were able to produce 
1 to 45 doses of MSCs from each BM sample in only 3 
passages demonstrating the efficacy of the process. We 
consider that it is very important to produce MSC from 
multiple donors for two main reasons: First, to limit the 
number of passages and second to have a large variabil-
ity of donors. Indeed, it has been suggested that if one 
donor is used to produce a multiplicity of MSC doses to 
treat a lot of patients, a potency bias may be observed 
[20]. Indeed, MSC from different donors may have dif-
ferent interferon-gamma responsiveness (low or high 
IDO inducers) and thus different potency. The outcome 
of a patient receiving MSC from a low or high responder 
may be different. On the other hand, cells that are subject 
to a high proliferative pressure and late passage random 
donor MSC could be less effective than early passage 
MSC [19]. These factors may explain the below expecta-
tion results of the phase III trial of random donor MSC in 
steroid-resistant GVHD with the ProchymalR industrial 
MSC product [20, 21]. Indeed, despite promising phase II 
trials, this phase III clinical trial did not meet its primary 
end point [22]. However, the product has been approved 
in two countries based on statistically significant benefits 
observed at certain disease sites.
Despite low passage cultures, we have been able to 
produce 464 MSC doses in 68 cultures that allowed us 
to create an allogeneic “off-the-shelf” MSC bank with a 
large number of frozen aliquots.
Up to June 2015, 290 MSC bags have been released 
and safely infused to patients included in our 6 current 
clinical protocols. We have evaluated cell viability and 
recovery from these thawed MSC products. Viability 
of fresh cells (90.3 ± 4.3 %) dropped to 76 ± 9.1 % after 
thawing (mean loss 14  %), but remained sufficient for 
meeting release criteria. These results compare favorably 
with those of Polchow et al. who describe a 20 % loss of 
viability (from 84.4 ± 9.4 to 67.4 ± 7.6 %) with thawing 
after short-time cryopreservation of human umbilical 
cord artery-derived cells (HUCAC) [23]. However, this 
difference can be explained by the fact that these cells 
were of different origin and cryopreserved in vials and 
not in bags. This was also the case for other studies that 
are difficult to compare because of dysparities in origin 
or culture stage of cells, cryopreservation and thawing 
methods [24–26].
Beside viability and recovery, freezing/thawing steps 
may also affect MSC potency. Indeed Galipeau et  al. 
reported recently that post-thaw cells have impaired 
immunosuppressive properties [27]. They demonstrate 
that post-thawed MSC up-regulate heat-shock proteins, 
are refractory to interferon–γ-induced up-regulation 
of indoleamine 2,3-dioxygenase (IDO) and are compro-
mised in suppressing CD3/CD28/-driven T cell prolifera-
tion. These properties were fully restored following 24 h 
of post-thaw MSC culture. In order to assess whether 
potency of our MSC presented similar kinetics, we 
thawed MSC bags and seeded cells back in culture for 
different periods of time before evaluating their viability, 
proliferation and potency (immunosuppressive prop-
erties and differentiation abilities). In accordance with 
Galipeau et al., we observed that after thawing, MSC are 
compromised in suppressing CD3/CD28/-driven T-cell 
proliferation. In our hands, 3  days of culture were nec-
essary to fully restore stable immunosuppressive proper-
ties. This correlated with a recovery of their proliferative 
potential, indicating that MSC probably need a 3-day 
recovery period after thawing. However, differentiation 
potential was maintained even when evaluated immedi-
ately after thawing. Nevertheless, the relevance of these 
in  vitro findings for the immunosuppressive efficacy of 
MSC is unknown. In vivo recovery of various cell prop-
erties may be quite different in the recipient body envi-
ronment. Indeed, Von Bahr et  al. have demonstrated 
that in vitro testing of MSC inhibitory capacity in MLC 
or mitogenic response to PHA did not correspond with 
in  vivo responses [19]. MSC potency defined by MLR 
assay may not be a good predictor of their in vivo effects. 
Krampera et  al. recently published a working proposal 
of the ISCT for immunological characterization of MSC 
[28]. It mentioned the urgent need as part of cell man-
ufacturing to develop and implement robust potency 
assays that may be associated with clinical effects and 
suggest different proposals including the use of IFN-γ 
and/or TNF-α in vitro primed MSC; investigation of cell-
surface markers expression by flow cytometry for char-
acterizing MSC immunological properties; the use of 
purified immune effector cells subsets in MLR instead of 
unselected peripheral blood mononuclear cells (PBMC), 
the of study some suppressor pathways induced by MSC 
such as IDO activation and the use of animal models to 
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evaluate MSC immunosuppressive properties The aim 
of standardization is to obtain reproducible and consist-
ent in vitro data that reflect immunological properties of 
MSCs infused to patients.
In this paper, we report optimization of clinical-grade 
large-scale MSC expansion with the set-up of a MSC bank 
and summarize 8 years of experience. The technical process 
in place leads to per donor cell yields that are sufficient for 
therapeutic purposes (median of 546  ×  10E6 MSC/cul-
ture =  4 doses of 2 ×  10E6 cells/kg for an average 75-kg 
patient). However, the manipulation of large quantities of 
T-flasks is a hurdle (time consuming, space consuming and 
open system) and, to avoid these disadvantages, we have 
validated the fully automated closed Quantum® bioreac-
tor for our process and published our observations [29]. 
The major advantages of the bioreactor were that (1) cells 
grow better in the Quantum® than in flasks, (2) working 
time is shorter especially at the final harvest step, and (3) all 
the feeding tasks are done automatically. This system thus 
allows production of large quantities of MSC. However, the 
cost of the device counterbalances its advantages, so that 
we did not implement it in our manufacturing strategy.
In the meantime, MSC have become considered as 
advanced therapy medicinal products (ATMP) by the 
European Medicines Agency (EMA), are under Euro-
pean Regulation N° 1394/2007 and must be produced in 
compliance with Good Manufacturing Practices (GMP). 
GMP requires thorough analysis of critical aspects such 
as donor screening, production processes and quality 
controls of expanded MSC (safety, identity and efficacy) 
[30]. Our MSC are produced under strict and defined 
parameters from donor screening to culture reagents and 
processes, using screened and irradiated FBS batches and 
subjected to extensive quality controls for safety (bacte-
riological analysis, endotoxin and mycoplasma detec-
tion), identity (FACS analysis according to ISCT criteria) 
and potency (immunosuppressive properties). Due to 
extensive washing and dilution of the cells before cryo-
preservation, residual reagents (trypsin–EDTA, FBS, and 
penicillin/streptomycin) are present at extremely low lev-
els (0.00138, 0.00024 and 0.000000286  %, respectively) 
after thawing. In addition, karyotype analysis performed 
on each batch has consistently shown genetic stability 
of the cells. We also showed that despite cell trapping in 
the lungs after intravenous infusion, this did not result in 
deleterious effects on lung function ([31]. In an attempt 
to improve aseptic conditions, GMP recommends the 
development of closed processes. For that purpose, we 
have successfully implemented in 2012 a new method 
for selection of mononuclear cells from BM samples 
with the fully closed SepaxR device [32]. Similarly, as 
explained earlier, we have validated the QuantumR bio-
reactor but didn’t implement it in our manufacturing 
process because of cost concerns. However, closed sys-
tems are not an absolute requirement of GMP and sev-
eral groups have described GMP-compliant culture 
processes in Cellstacks [33] or T-flasks [15]. We are now 
in the last phase of GMP implementation in our process 
of MSC banking. Briefly, major changes applied to the 
process concern the environment (extensive monitor-
ing, class B room with adapted controls of work environ-
ment and equipment, clothes, hygienic and safety rules, 
sanitization of the clean room and maintenance/checking 
of equipment), technical process (replacement of some 
reagents, use of cellstacks instead of T-Flasks, separa-
tion of people involved in production and in quality con-
trol), quality control (formal validation of all internal QC 
methods and use of GMP-certified laboratories for sub-
contracted analyses, quarantine status before release of 
batches by a qualified person), reagents (quarantine sta-
tus until release by the qualified person according to their 
specifications) and a considerable extension of the docu-
mentation system and traceability of all processes.
Conclusion
In conclusion, we report here an efficient clinical-grade 
MSC banking activity in place for more than 7  years. 
This activity now has to be performed in accordance 
with GMP requirements. A significant challenge remains 
the development and implementation of standardized 
potency assays and the demonstration of a correlation 
with relevant endpoints in clinical trials.
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